Leukemia

The FDA granted an accelerated approval to asciminib for newly diagnosed Ph+ chronic myeloid leukemia in the chronic phase.

The FDA granted a fast track designation to HC-7366 for adults with relapsed or refractory acute myeloid leukemia.

Asciminib is a promising agent for frontline chronic myeloid leukemia, Jorge Cortes, MD, explained.

Older adults with acute myeloid leukemia treated with anthracyclines tended to live longer, but also had more time spent in the hospital compared with those treated with HMAs.

Pediatric and young adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia are receiving tisagenlecleucel in earlier lines of therapy.

Minimal residual disease status was linked to progression-free survival in patients with chronic lymphocytic leukemia in the first-line treatment setting and with time-limited therapy.

Adding blinatumomab to consolidation chemotherapy provided a significant OS benefit in MRD-negative B-cell precursor acute lymphoblastic leukemia.

Taking mismatched unrelated donors into consideration may increase donor numbers, especially for patients with minority ancestry who are seeking hematopoietic cell transplantation.

A fixed-duration treatment combining acalabrutinib and venetoclax, with or without obinutuzumab, significantly extended progression-free survival in patients with previously untreated chronic lymphocytic leukemia.

The FDA granted the investigational menin-MLL inhibitor DSP-5336 fast track designation for KMT2A-rearranged/NPM1-mutant acute myeloid leukemia.

Improving progression-free survival and confirming results with MRD testing were treatment qualities that patients with CLL reported were more important than other factors.

Patients with previously untreated chronic lymphocytic leukemia treated with venetoclax plus obinutuzumab either with or without ibrutinib experienced significant PFS improvements.

The health care team should provide an open forum for patients with chronic myeloid leukemia to discuss how adverse events from treatment affect daily function.

Patients with newly diagnosed, high-risk acute promyelocytic leukemia treated with a combination strategy of ATO plus ATRA and idarubicin experienced improvements in event-free survival.

The FDA approved blinatumomab for patients 1 month or older with CD19-positive, Philadelphia chromosome–negative, B-cell precursor acute lymphoblastic leukemia.

Asciminib led to a superior 48-week major molecular response rate compared with investigator-selected tyrosine kinase inhibitors for Ph-positive chronic phase chronic myeloid leukemia.

Uproleselan plus chemotherapy missed the overall survival end point in the phase 3 trial assessing the combination in patients with relapsed/refractory acute myeloid leukemia.

Second-line venetoclax may lead to monthly cost savings vs second-line BTK inhibitor for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

Recent data from a phase 3b trial support venetoclax as a CLL treatment option for those with or without B-cell receptor–associated kinase inhibitor treatment.

Accelerated approval was granted by the FDA to ponatinib plus chemo for adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.

The antibody-drug conjugate inotuzumab ozogamicin was approved by the FDA for the treatment of patients aged 1 year and older with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia.

An orphan drug designation has been granted by the FDA to ocifisertib as a potential treatment option in acute myeloid leukemia.

It may be feasible to use brexucabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell acute lymphoblastic leukemia with central nervous system involvement.

A fast track designation has been granted by the FDA to the novel BTK degrader, NX-5948, for adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma who were treated with at least two lines of therapy, including a BTK inhibitor and a BCL2 inhibitor.

Treatment with asciminib for newly diagnosed, Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase induced statistically significant and clinically meaningful major molecular response benefits compared with standard-of-care TKIs.

SLS009 has been granted fast track status from the FDA to be considered as a potential therapeutic option for relapsed or refractory acute myeloid leukemia.

The major molecular response rate for asciminib at week 156 continued to be higher than with bosutinib.

Most biomarkers in subgroups of patients with treatment-naive chronic lymphocytic leukemia or small lymphocytic lymphoma without del(17p) derived benefit from zanubrutinib vs bendamustine plus rituximab.

At a median 39 months of follow-up, zanubrutinib reduced the risk of disease progression by 32% compared with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.

Acalabrutinib, whether as monotherapy or as part of a combination, demonstrated superior progression-free survival outcomes compared to obinutuzumab and chlorambucil.